Cite
HARVARD Citation
Papp, K. et al. (2013). SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis. Annals of the rheumatic diseases. p. A680. [Online].